QUALITROL DISINFECTANT LIQUID

Indications

• Rectal and anal disorders
• Haemorrhoids
• Pruritus ani

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: For rectal use using aerosol spray: 1 spray up to 3 times a day for no longer than 7 days without medical advice. For ointment: apply several times daily, for short-term use only.

Mechanism of action

Phenol exerts its effects by acting as a potent proteolytic agent. At concentrations of 5% to 7%, it can dissolve tissue through proteolysis. When injected near a nerve, it produces chemical neurolysis, affecting nerve fibers nonselectively. Local anesthetic effects are typically observed within 5 to 10 minutes of application.

Pharmacodynamics

Phenol's pharmacodynamic properties include its ability to cause tissue dissolution and local anesthesia. The local anesthetic effects result from its action on the nerve fibers, leading to a temporary loss of sensation in the affected area. The proteolytic action can assist in the treatment of various skin and mucosal conditions by facilitating tissue breakdown.

Pharmacokinetics

Phenol is absorbed through mucosal surfaces when applied locally. Its metabolism involves biological oxidation and phase I functionalization, primarily through cytochrome P450 enzymes. The elimination of phenol occurs through metabolic pathways, and it can be detected in urine as a result of its metabolism.

Contra-indications

• Infection
• Known hypersensitivity to phenol or its components

Adverse effects

• Local irritation
• Burning sensation
• Paraesthesia
• Vision disorders
• Skin reactions
• Adrenal suppression

Interactions

• Caution with other local anesthetics due to potential additive effects

Precautions

• Use for short periods only-no longer than a few days
• Avoid excessive application, especially on sensitive areas
• Consult product literature for specific guidelines

Pregnancy

Data on the use of phenol during pregnancy is limited; caution is advised.

Breast-feeding

Limited information available; caution is recommended when used in breastfeeding mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Ointment
• Suppository
• Aerosol spray

Indications

• Angina pectoris
• Diagnostic procedures in medicine
• Recreational use for psychoactive effects

Dosage

Children: Refer to established clinical guidelines or specific product information for dosing recommendations.

Adults: Refer to established clinical guidelines or specific product information for dosing recommendations.

Mechanism of action

Amyl nitrite acts by releasing nitric oxide (NO) in the body, which leads to the relaxation of smooth muscle and vasodilation. This effect is primarily mediated through the activation of guanylate cyclase, leading to increased levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, resulting in decreased vascular resistance and increased blood flow, especially to the coronary arteries.

Pharmacodynamics

The pharmacodynamic effects of amyl nitrite include the relaxation of vascular smooth muscle, leading to decreased preload and afterload on the heart, which can result in a reduction of myocardial oxygen demand. The onset of action is rapid, typically within minutes, and effects can last for a short duration, making it suitable for acute relief of anginal symptoms. The drug can also cause hypotension, tachycardia, and headache due to its vasodilatory effects.

Pharmacokinetics

Amyl nitrite is rapidly absorbed after inhalation or sublingual administration. It has a very short half-life, usually around 3 to 5 minutes, leading to quick onset of action. The metabolism occurs primarily in the liver via conjugation with glucuronic acid, and the excretion is predominantly via urine. The rapid clearance of the drug necessitates frequent dosing for sustained effects, particularly in the management of angina.

Contra-indications

• Hypersensitivity to amyl nitrite or any of its components
• Severe anemia
• Increased intracranial pressure
• Hypotension
• Severe heart failure

Adverse effects

• Headache
• Dizziness
• Flushing
• Tachycardia
• Hypotension
• Nausea
• Vomiting
• Methemoglobinemia

Interactions

• Concurrent use with phosphodiesterase type 5 inhibitors (e.g., sildenafil) can lead to profound hypotension
• Use with other antihypertensive agents may enhance hypotensive effects
• Alcohol may exacerbate vasodilatory effects

Precautions

• Use with caution in patients with pre-existing cardiovascular conditions
• Monitor blood pressure regularly during treatment
• Caution in patients with a history of substance abuse
• Avoid use in patients with severe liver or kidney impairment

Pregnancy

Amyl nitrite is classified as category C. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether amyl nitrite is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a tightly closed container at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Amyl nitrite inhalation solution

Indications

• Bacterial infections
• Pneumonia
• Meningitis
• Syphilis
• Endocarditis
• Skin and soft tissue infections

Dosage

Children: Paediatric dosing for benzylpenicillin is determined by the child's weight and the severity of the infection. Refer to the BNF for Children for specific dosing guidelines.

Adults: The usual adult dose for benzylpenicillin varies based on the type and severity of the infection. It is generally administered via intramuscular or intravenous routes. For severe infections, doses may range from 1 to 4 million units every 4 to 6 hours.

Mechanism of action

Benzylpenicillin exerts its antibacterial effects by inhibiting the synthesis of bacterial cell walls. It binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, disrupting the transpeptidation process, which is crucial for cross-linking peptidoglycan layers. This inhibition leads to cell lysis and death of the bacteria.

Pharmacodynamics

Benzylpenicillin demonstrates time-dependent bactericidal activity, meaning its effectiveness is related to the duration of time the drug concentration remains above the minimum inhibitory concentration (MIC) for the target bacteria. It has a narrow spectrum of activity, primarily targeting Gram-positive cocci and some Gram-negative rods.

Pharmacokinetics

Benzylpenicillin is typically administered parenterally due to poor oral absorption. It is rapidly distributed throughout the body and can penetrate various tissues, including the central nervous system during inflammation. The drug is primarily eliminated by renal excretion, with a half-life of approximately 30 minutes to 1 hour in healthy individuals. Dosage adjustments may be necessary in patients with renal impairment.

Interactions

• leflunomide+benzylpenicillin: Unknown (increases exposure)
• nitisinone+benzylpenicillin: Unknown (increases exposure)
• teriflunomide+benzylpenicillin: Unknown (increases exposure)

Pregnancy

Benzylpenicillin is generally considered safe to use during pregnancy, as it is a penicillin antibiotic and has a long history of use.

Breast-feeding

Benzylpenicillin is excreted in breast milk in small amounts, but it is not expected to have adverse effects on a nursing infant.

Storage

Store in a cool, dry place, protected from light. Reconstituted solutions should be used promptly or stored in a refrigerator and used within a limited time frame.

Formulations

• Benzylpenicillin injection

Indications

• Prevention of malaria
• Treatment of acute malaria attacks
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Amoebic liver abscess

Dosage

Children: Refer to BNF for Children for specific dosing information based on the condition and age of the child.

Adults: Refer to BNF for specific dosing information based on the condition being treated.

Mechanism of action

Chloroquine exerts its pharmacological effects primarily by interfering with the heme detoxification pathway of the Plasmodium species. It accumulates in the food vacuole of the parasite, preventing the conversion of toxic heme into non-toxic hemozoin, thereby leading to the accumulation of toxic heme and ultimately resulting in the death of the parasite. Additionally, chloroquine may modulate immune responses, which contributes to its use in autoimmune conditions.

Pharmacodynamics

Chloroquine exhibits a dose-dependent response, with higher concentrations leading to enhanced antimalarial activity. It is known to have a long half-life, allowing for once or twice daily dosing in many cases. The drug's effects can be influenced by the presence of food and its pharmacological interactions with other drugs, which can alter its efficacy and safety profile.

Pharmacokinetics

Chloroquine is well absorbed from the gastrointestinal tract, with peak plasma concentrations attained approximately 2 to 6 hours after oral administration. It is extensively distributed in tissues, especially in the liver, lungs, and spleen. The drug is metabolized in the liver and has a long elimination half-life, ranging from 1 to 2 months, which can lead to drug accumulation in chronic use. The principal route of elimination is renal, through both glomerular filtration and tubular secretion.

Interactions

• chloroquine+agalsidasealfa: Severe (decreases effects)
• chloroquine+agalsidasebeta: Severe (decreases effects)
• chloroquine+penicillamine: Severe (increases risk of haematological toxicity)
• chloroquine+rabiesvaccine: Severe (decreases efficacy)
• chloroquine+intradermal: Severe (decreases efficacy)
• chloroquine+remdesivir: Severe (decreases effects)
• chloroprocaine+sulfonamides: Severe (decreases effects)
• chloroquine+praziquantel: Moderate (decreases exposure)
• oral antacids+chloroquine: Unknown (decreases absorption)
• chloroprocaine+antiarrhythmics: Unknown (increases risk of cardiovascular adverse effects)

Pregnancy

Consult the BNF for specific guidance on use during pregnancy.

Breast-feeding

Consult the BNF for specific guidance on use during breastfeeding.

Storage

Store in a cool, dry place away from light.

Indications

• Contraception
• Regulation of menstrual cycles
• Treatment of polycystic ovary syndrome (PCOS)
• Management of endometriosis
• Treatment of menstrual disorders

Dosage

Children: Ortho contraceptives are generally not prescribed for individuals under the age of 16 without careful consideration. Consultation with a healthcare provider is essential for determining appropriate use in younger populations.

Adults: The specific dosage of Ortho varies based on the formulation and the individual's health status. It is important to follow the prescribing information provided by healthcare providers.

Mechanism of action

The active ingredients in Ortho contraceptives work by inhibiting ovulation, thickening the cervical mucus to prevent sperm penetration, and altering the endometrial lining to prevent implantation of a fertilized egg. This multi-faceted approach effectively reduces the likelihood of conception.

Pharmacodynamics

Estrogens and progestins exert their effects by binding to estrogen and progesterone receptors, respectively. This binding leads to changes in gene expression that suppress gonadotropin release, ultimately inhibiting follicular development and ovulation. The alteration of the endometrial environment makes it less favorable for implantation, thereby contributing to contraceptive efficacy.

Pharmacokinetics

Ortho contraceptives are absorbed rapidly from the gastrointestinal tract, with peak plasma concentrations achieved within 1 to 3 hours after administration. These drugs are metabolized primarily in the liver, with various metabolic pathways involved, including conjugation and hydroxylation. The elimination half-lives of the individual components can vary, but they are generally excreted in urine and feces. The pharmacokinetics can be influenced by factors such as concurrent medications, liver function, and gastrointestinal health.

Contra-indications

• Hypersensitivity to any component of the formulation
• Severe liver disease
• Severe renal impairment
• Undiagnosed vaginal bleeding
• History of thromboembolic disorders

Adverse effects

• Nausea
• Vomiting
• Headache
• Breast tenderness
• Mood changes
• Weight gain
• Increased risk of thromboembolic events
• Irregular bleeding patterns

Interactions

• Antibiotics may reduce the effectiveness of the contraceptive effect
• Anticonvulsants may also decrease efficacy
• St. John's Wort may reduce plasma concentrations
• Certain antiretroviral medications may interact

Precautions

• Use with caution in patients with a history of hypertension
• Monitor for signs of thromboembolism
• Regular check-ups recommended for long-term users
• Consider alternative contraception methods in certain populations

Pregnancy

Use of this drug is contraindicated during pregnancy due to potential harm to the fetus. It can lead to congenital malformations and other serious complications.

Breast-feeding

The drug may be secreted in breast milk; therefore, caution is advised. Consult healthcare professionals for alternative contraceptive methods if breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Transdermal patches
• Vaginal rings

Indications

• Phosphate deficiency
• Hypophosphatemia
• Bone mineralization disorders
• Renal osteodystrophy

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

Orthophosphate functions primarily as a source of inorganic phosphate in biochemical reactions. It is involved in the phosphorylation of molecules which is critical for the synthesis of ATP and the regulation of metabolic pathways. Its presence is vital in the formation of nucleotides and phospholipids, which are essential for cellular function and structure. The pathways it influences include nitrogen metabolism, biotin metabolism, D-alanine metabolism, D-glutamine and D-glutamate metabolism, lysine biosynthesis, taurine metabolism, and the TCA cycle.

Pharmacodynamics

Orthophosphate contributes to the regulation of various physiological processes, including energy metabolism and cellular signaling. It is essential for the maintenance of acid-base balance and the proper functioning of enzymes that are dependent on phosphate groups. Additionally, it plays a role in bone mineralization and is a key factor in the regulation of calcium metabolism. Its pharmacodynamic effects are closely linked to its role in ATP synthesis and the energy status of cells.

Pharmacokinetics

Orthophosphate is readily absorbed in the gastrointestinal tract and is distributed throughout the body. It is primarily excreted by the kidneys, with a regulated reabsorption process that maintains homeostasis. The half-life of orthophosphate in the body is relatively short, necessitating a continuous supply through dietary sources or supplementation. Its pharmacokinetic properties are influenced by renal function, dietary intake, and hormonal regulation, particularly by parathyroid hormone and vitamin D.

Pregnancy

Orthophosphate is typically considered safe during pregnancy when used appropriately; however, it is always best to consult a healthcare provider.

Breast-feeding

Orthophosphate is generally regarded as safe during breastfeeding; it is important to follow medical advice.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Allergic contact dermatitis
• Skin sensitization
• Use in hair dyes and cosmetic products

Dosage

Children: Refer to specific product guidelines and local regulations for appropriate use, as para is primarily used in topical applications and not typically dosed systematically.

Adults: Refer to specific product guidelines and local regulations for appropriate use, as para is primarily used in topical applications and not typically dosed systematically.

Mechanism of action

The mechanism of action of para, particularly in relation to its sensitizing properties, involves the formation of benzoquinone from para-phenylenediamine. This metabolite is implicated in allergic reactions by modifying proteins, leading to the activation of the immune response in sensitized individuals.

Pharmacodynamics

Para exhibits skin-sensitizing properties, which can lead to allergic dermatitis upon exposure. The compound can cause a range of reactions, from mild irritation to severe allergic responses, depending on the individual's sensitivity and the concentration of the compound used. Its effects are primarily local, affecting the skin at the site of contact.

Pharmacokinetics

The pharmacokinetics of para are not well-documented in the literature. However, it is known that upon dermal exposure, it can be absorbed through the skin, leading to systemic effects in sensitized individuals. Metabolism may occur in the liver, with the potential formation of reactive metabolites contributing to its toxicity. Excretion primarily occurs via urine.

Interactions

• bisphosphonates+parathyroidhormone: Severe (decreases effects)
• paracetamol+topicalprilocaine: Moderate (increases risk of methaemoglobinaemia)
• paracetamol+topicalanaesthetics,local: Moderate (increases risk of methaemoglobinaemia)
• paracetamol+prilocaine: Moderate (increases risk of methaemoglobinaemia)
• paracetamol+coumarins: Unknown (increases anticoagulant effect)
• paracetamol+dapsone: Unknown (increases risk of methaemoglobinaemia)
• imatinib+paracetamol: Unknown (increases risk of hepatotoxicity)
• pitolisant+paracetamol: Unknown (decreases exposure)
• rifampicin+paracetamol: Unknown (decreases exposure)

Indications

• Pain relief
• Inflammation reduction
• Fever reduction
• Various therapeutic applications depending on specific phenyl-containing compounds

Dosage

Children: Refer to BNF for Children for dosage recommendations.

Adults: Refer to specific phenyl-containing compound for dosage recommendations.

Mechanism of action

Compounds containing the phenyl group often act by modulating neurotransmitter pathways, inhibiting cyclooxygenase enzymes, or interacting with various receptor sites, depending on the specific drug structure. For example, phenyl-containing analgesics may work by blocking the synthesis of prostaglandins, thus reducing pain and inflammation.

Pharmacodynamics

The pharmacodynamics of phenyl-containing compounds vary widely based on the specific drug, but many exhibit effects such as analgesia, anti-inflammatory activity, or antipyretic properties. The phenyl group can enhance lipophilicity, allowing for better absorption and distribution in the body.

Pharmacokinetics

The pharmacokinetics of phenyl-containing compounds are dependent on their chemical structure. Generally, these compounds have varied absorption rates, metabolism predominantly through hepatic pathways, and excretion primarily via renal mechanisms. The presence of the phenyl group can influence the half-life and bioavailability of the drug.

Pregnancy

Safety during pregnancy is not established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether phenyl is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Nutritional supplementation
• Metabolic disorders
• Potential use in energy metabolism enhancement

Dosage

Children: Refer to the BNF for Children for appropriate dosing information as it may vary based on indication and formulation.

Adults: Refer to specific clinical guidelines or consult the BNF for appropriate dosing information as it may vary based on indication and formulation.

Mechanism of action

Phenylpropionate is primarily involved in metabolic processes. It may exert its effects through modulation of fatty acid metabolism and energy homeostasis. Specific pathways include the involvement in β-oxidation and potential interactions with peroxisome proliferator-activated receptors (PPARs), which regulate gene expression related to lipid metabolism.

Pharmacodynamics

Phenylpropionate exhibits properties that can influence lipid metabolism and energy utilization within the body. Its effects on fatty acid oxidation can lead to alterations in energy expenditure. The pharmacodynamic profile is characterized by its ability to impact metabolic pathways, although detailed receptor interactions remain less defined.

Pharmacokinetics

The pharmacokinetic properties of phenylpropionate, including absorption, distribution, metabolism, and excretion, have not been extensively documented in the available literature. As a carboxylic acid derivative, it is likely absorbed through the gastrointestinal tract, metabolized primarily in the liver, and excreted via the kidneys. Further studies would be needed to define specific parameters such as half-life and bioavailability.

Pregnancy

There is insufficient data on the safety of phenylpropionate in pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution should be exercised when phenylpropionate is administered to a nursing mother. The effects on the breastfeeding infant are not well studied.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Major depressive disorder
• Generalized anxiety disorder
• Schizophrenia
• Bipolar disorder
• Obsessive-compulsive disorder

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines, as pediatric dosages are often calculated based on weight and the specific condition being treated.

Adults: Refer to specific prescribing information for individual tertiary drugs, as dosing can vary widely based on the compound and patient characteristics.

Mechanism of action

Tertiary compounds, particularly tertiary amines, often act as antagonists or modulators of neurotransmitter receptors in the central nervous system. They may inhibit reuptake of neurotransmitters like serotonin, norepinephrine, and dopamine, enhancing their availability in the synaptic cleft. This modulation can lead to altered mood, cognition, and perception, which is beneficial in treating conditions such as depression and schizophrenia.

Pharmacodynamics

The pharmacodynamic effects of tertiary compounds can vary widely depending on the specific drug. Generally, they exhibit a range of effects including sedation, anxiolytic activity, and mood elevation. Due to their ability to interact with multiple receptor types, including adrenergic, muscarinic, and histaminergic receptors, they may also produce side effects such as sedation, anticholinergic effects, and weight gain.

Pharmacokinetics

Tertiary compounds are usually well-absorbed following oral administration, with peak plasma concentrations occurring within a few hours. They are extensively metabolized in the liver, primarily through cytochrome P450 enzymes, leading to various active and inactive metabolites. The elimination half-lives can vary, influencing dosing schedules. They are typically excreted in urine, and their pharmacokinetic profiles can be affected by factors such as age, liver function, and potential drug interactions.

Pregnancy

The safety of tertiary medications during pregnancy varies. Consult specific drug references for individual agents.

Breast-feeding

Consult specific drug references for individual agents regarding use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Mechanism of action

Phenol is a potent proteolytic agent. Concentrations in the 5% to 7% range dissolve tissue on contact via proteolysis. In high concentrations when injected next to a nerve, phenol produces a chemical neurolysis which is nonselective across nerve fiber size and most prominent on its outer aspect. Local anesthetic effects occur within 5-10 minutes. The effects of monoamine depletors and monoamine denervators on phenol induced tremor were studied in mice. The tremor induced by phenol was enhanced by pretreatment with reserpine or tetrabenazine, but not with syrosingopine. However, alpha-methyl-p-tyrosine, p-chlorophenylalanine or 6-hydroxydopamine did not affect the tremor. These results suggest that the depletion of central monoamines as a whole contribute to the enhancement of the tremor induced by phenol.

Mechanism of action

FROM STUDIES OF THE INTRACUTANEOUS SENSITIZATION OF GUINEA-PIGS USING PARA-PHENYLENEDIAMINE, HYDROQUINONE, QUINHYDRONE AND BENZOQUINONE, IT HAS BEEN SUGGESTED THAT BENZOQUINONE FORMATION PLAYS AN IMPORTANT ROLE IN THE ALLERGIC ACTION OF PARA-PHENYLENEDIAMINE.